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RECENT ADVANCES IN ENDOCRINOLOGY
SGLT2i Use in Non-Diabetics
Sarah Nadeem1, Masooma Rana2, Kaleem S. Ahmed3, Sanjay Kalra4,5

Introduction
Sodium Glucose Co-Transporter 2 inhibitors (SGLT2i), which
include canagliflozin, dapagliflozin, empagliflozin and
ertugliflozin,
are
insulin-independent
oral
antihyperglycaemic medications that uniquely reduce
glucose reabsorption in the proximal convoluted tubules
of the kidney resulting in glycosuria and natriuresis. These
drugs are eﬀective in the treatment of any stage of type 2
diabetes, as they can be used in states of insulin resistance
and beta-cell dysfunction. There are a number of diﬀerent
SGLTi available worldwide (see Table 1). In Pakistan, we
currently have dapagliflozin and empagliflozin licensed by
the Drug Regulation Authority of Pakistan for use in
diabetes. This paper aims to summarize unconventional
non diabetic uses of SGLT2i that shown promising results.1
Table-1: List of available SGLT2i worldwide and their respective year of approval by the
US Food and Drug Administration (FDA) and European Medicines Agency
(EMA)2,3
SGLT2i

Body of Approval for Diabetics

Year of Approval

Dapagliflozin

FDA
EMA

2014
2012

Canagliflozin

FDA
EMA

2013
Pending

Empagliflozin

FDA
EMA

2014
2014

Ertugliflozin

FDA
EMA

2017
2017

Use of SGLT2 inhibitors in Diabetes
The 2019 guidelines from the American Diabetes
Association recommend lifestyle modifications and
metformin as first line treatment to reach target HbA1c in
patients with type 2 DM; if these therapies fail to achieve
goal then existing comorbidities should be considered
including cardiovascular disease, congestive heart failure,
chronic kidney disease and obesity to guide the decision
for treatment. SGLT2i are recommended as preferred
adjunct therapy in these four conditions, if the patient has
an adequate estimated glomerular filtration rate (eGFR)4-7
as SGLT2i have demonstrated multiple beneficial eﬀects
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along with glucose lowering in a number of clinical
trials.5-7
Sodium Glucose Co-Transporter 2 (SGLT2) is an essential
protein primarily responsible for physiological glucose
reabsorption. It is responsible for 90 percent of glucose
uptake from proximal renal tubules, with SGLT1
reabsorbing the remaining 10%. Inhibition of SGLT2 results
in blockage of this glucose reabsorption mechanism,
causing glycosuria and resulting lowered blood glucose
levels.8 A distinct benefit with their use is that their glucose
lowering eﬀect is independent of beta cell function or
insulin sensitivity thus carrying low risk for hypoglycaemia
as well as potential for use in Type 1 Diabetics (approved in
Europe, rejected in the US by FDA).9 Since their
introduction into clinical practice in 2013, SGLT2i drugs
have demonstrated improved glucose control, reduced
blood pressure, significant reductions in HbA1c, and
weight loss in persons with type 2 diabetes.
Recent studies assessing the eﬀects of SGLT2i on associated
cardiac and renal disease in diabetic patients have shown
cardiovascular risk reduction, decreased heart failure
mortality and renal protective eﬀects.10-12 EMPA-REG
OUTCOME was the first trial on the renal benefits in these
drugs—published in 2016—showing that empagliflozin
was associated with a slower progression of chronic kidney
disease and fewer renal complications in type 2 DM
patients with high cardiovascular risk.10 EMPA-REG also
demonstrated reduced cardiovascular complications with
empagliflozin, with a 38 percent risk reduction from
cardiovascular-related deaths in type 2 diabetics.11
Dapagliflozin demonstrated reductions in cardiovascular
hospitalizations and deaths in the DECLARE-TIMI trials.12
Due to the success of SGLT2i in these settings, they are
being considered for their potential cardiovascular benefits
in nondiabetics as well.
SGLT2i and Cardiovascular Outcomes
All SGLT2i have demonstrated significant risk reduction in
hospitalization for heart failure13 yet a class eﬀect on major
cardiovascular events (in studies so far) has not been seen.
According to the DAPA-HF trial, dapagliflozin lowers the risk
of worsening heart failure and cardiovascular related death
by 26 percent in patients with pre-existing heart failure
with a low ejection fraction, when compared to placebo;
regardless if the patient has diabetes or not.14 The positive
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results of the DAPA-HF trial allowed for the dapagliflozin
(Farxiga - AstraZeneca) to be the first SGLT2i to be approved
by the US Food and Drug Administration (FDA) for use in
nondiabetic heart failure patients with reduced ejection
fraction.15 Along with this, a recent study found that
canagliflozin and empagliflozin showed a larger reduction
in heart failure risk than other drugs for type 2 diabetes.16
SGLT2i drugs are believed to be useful in the setting of
heart failure due to it being a diuretic and the resulting
volume reduction; however, there is still more research to
be done to see the other eﬀects these drugs have in the
setting of heart failure. More trials looking at the eﬀects
SGLT2i on the cardiovascular system are currently
underway, to DELIVER trial with results available in 2021 is
assessing at dapagliflozin’s eﬀects on patients with heart
failure but preserved ejection fraction.1,17

Obesity
These drugs may have a role to play potentially as obesity
treatment independent of diabetes as well. When used
alone, the glucose/calorie loss in the urine is not enough
to oﬀ-set food intake and yield significant weight loss.
However, a number of studies have shown that when
SGLT2i are taken adjuvantly with other agents that reduce
appetite, there is a greater reduction in body weight. GLP1RA coupled with SGLT2i have demonstrated moderate
weight loss in the range of 4.5-5.7kg in patients without
diabetes.20 A clinical trial also showed meaningful
reductions in body weight in obese non-diabetic patients
when on canagliflozin and phentermine either in
combination or each drug alone.21

Kidney disease
Dapagliflozin has shown beneficial eﬀects on the renal
system, with studies suggesting that it has a role in
decreasing hyperfiltration, albuminuria, and tubular injury
in both diabetic and non-diabetic patients. SGLT2i cause
natriuresis and increased sodium delivered to the macula
densa activates tubuloglomerular feedback which results
in intraglomerular pressure reduction due to constriction
of the aﬀerent arteriole, and decrease in the glomerular
filtration rate. Studies have shown that these drugs are
associated with decreased urinary proximal tubular injury
biomarkers and reduction in inflammation and fibrosis
formation, further suggesting its direct eﬀects on the
kidney.18 This has led to the approval of SGLT2i worldwide
for the expanded indication of reducing risk for end-stage
renal disease in diabetic patients with chronic kidney
disease.15

Other benefits
SGLT2i may also have a unique role in the prevention of
early stage, well-diﬀerentiated lung adenocarcinoma and
precancerous lung lesions, as recent studies have shown
SGLT2 expression and activity in these tumours.
Canagliflozin was seen to have a role in increasing survival
rates in mice by limiting glucose supply in these cells.
Modified PET scans were used in the study to assess the
activity of SGLT2, which has the potential to be useful in
diagnosis of early lung cancers. However, the study had
limitations concerning the fact that the therapeutic eﬀects
of canagliflozin were reversible due to upregulation of
SGLT2. Along with this, the results of the study cannot be
attributed to the knockout of SGLT2 in the cancer alone,
and survival rates can be due to lowering of blood glucose
rather than the inhibition of glucose uptake in the
tumour.22

There is also promise with the combination therapy of renin
angiotensin system (RAS) blockers and SGLT2i in nondiabetic patients with proteinuria, as RAS blocker therapy
can be insuﬃcient in many patients, leading to worsening
kidney function - as there would be a reduction of the
glomerular filtration rate, and subsequent inhibition of the
RAS.19 In current non-diabetic rat and mice models, results
have been seen to vary. Other theories regarding the
renoprotective eﬀects of SGLT2i are attributed to a
decrease in blood pressure, weight loss, and glycaemic
control. Clinical trials are required to determine if the renal
benefits of dapagliflozin are independent from the
antihyperglycaemic eﬀects.18 One trial was stopped earlier,
in March 2020 by AstraZeneca; The Dapagliflozin And
Prevention of Adverse outcomes in Chronic Kidney Disease
(DAPA-CKD) Phase III trial for dapagliflozin in patients with
chronic kidney disease (CKD) with and without Diabetes
type 2 demonstrated overwhelming eﬃcacy and benefits

Adverse eﬀects
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earlier than originally anticipated.

SGLT2i may cause the following adverse eﬀects, although
rare. There is an increased risk of genital tract infections and
lower limb amputation with the use of SGLT2i. Genital tract
infections are seen twice as many times in patients taking
SGLT2i when compared to placebo groups, but many of
these cases were seen to be manageable.7 The CANVAS trial
found that canagliflozin increased the risk of lower limb
amputation by 97%; however, empagliflozin had no such
associations.1 Volume depletion may contribute to
decreased circulation in the distal artery beds, leading to
increased risk for amputation. Genitourinary infections may
occur due to glycosuria, warm/moist environment and
decreased immunity in diabetics (mild/moderate
infections); however, most patients did not require the
need to discontinue medicines and were manageable.1
Patients with lowered eGFR (<30 mL/min/1.73m2) should
not be started on these drugs, and if eGFR declines, then
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Table-2: Available SGLT2i in Pakistan.
SGLT2i licensed for use in Pakistan
Formulation and dose

Frequency

Dapagliflozin 5mg
Dapagliflozin 10mg
Dapagliflozin 5mg in combination with metformin 850mg
Dapagliflozin 5mg in combination with metformin 1000mg
Empagliflozin 10mg
Empagliflozin 25mg
Empagliflozin 12.5mg in combination with metformin 500mg
Empagliflozin 12.5mg in combination with metformin 850mg
Empagliflozin 12.5mg in combination with metformin 1000mg

Once a day
Once a day
Twice a day
Twice a day
Once a day
Once a day
Twice a day
Twice a day
Twice a day

therapy should be discontinued as the eﬃcacy and safety
of empagliflozin have not been established in patients with
severe renal impairment.

10.

11.

12.

13.
14.

15.

Conclusion
SGLT2i uniquely reduces glucose reabsorption in the
proximal convoluted tubules of the kidney resulting in
glycosuria and natriuresis. The indications for their use
continue to expand rapidly from patients with diabetes to
heart failure and CKD, with others likely to be added in the
future.

16.

References
1.

2.

3.

4.

5.

6.

7.

8.

Simes BC, Mac Gregor GG. Sodium-Glucose Cotransporter-2 (SGLT2)
Inhibitors: A Clinician’s Guide. Diabetes, Metabolic Syndrome and
Obesity: Targets and Therapy. 2019.
Nomura S, Sakamaki S, Hongu M, Kawanishi E, Koga Y, Sakamoto T,
et al. Discovery of canagliflozin, a novel C-glucoside with thiophene
ring, as sodium-dependent glucose cotransporter 2 inhibitor for the
treatment of type 2 diabetes mellitus (1). J Med Chem. 2010;53:635560
Grempler R, Thomas L, Eckhardt M, Himmelsbach F, Sauer A, Sharp
DE, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: Characterisation and comparison with
other SGLT-2 inhibitors. Diabetes, Obes Metab. 2012;14:83-90
Johnson EL, Feldman H, Butts A, Billy CDR, Dugan J, Leal S, et al. Standards of medical care in diabetes—2019 abridged for primary care
providers. Clin Diabetes. 2019;37: 11-34
Monami M, Nardini C, Mannucci E. Eﬃcacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: A meta-analysis of
randomized clinical trials. Diabetes, Obes Metab. 2014;16:457-466
Zaccardi F, Webb DR, Htike ZZ, Youssef D, Khunti K, Davies MJ. Eﬃcacy and safety of sodium-glucose co-transporter-2 inhibitors in
type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes, Obes Metab. 2016;18:783-94
Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: Rationale
and clinical prospects. Nature Reviews Endocrinology. 2012;8:495502
Mogensen CE. Maximum tubular reabsorption capacity for glucose
and renal hemodynamics during rapid hypertonic glucose infusion
in normal and diabetic subjects. Scand J Clin Lab Invest. 1971;28:101109

17.

18.
19.

20.

21.

22.

Europe embraces, FDA rejects use of SGLT inhibitors for type 1 diabetes [Internet]. [cited 2020 Jul 12]. Available from:
https://www.healio.com/news/endocrinology/20190723/europeembraces-fda-rejects-use-of-sglt-inhibitors-for-type-1-diabetes
Wanner C, Inzucchi SE, Lachin JM, Fitchett D, Von Eynatten M,
Mattheus M, et al. Empagliflozin and progression of kidney disease
in type 2 diabetes. N Engl J Med. 2016;375:323-34
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al.
Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-28
Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J
Med. 2019; 380:347-357
Giugliano D, Esposito K. Class eﬀect for SGLT-2 inhibitors: A tale of 9
drugs. Cardiovasc. Diabetol. 2019:18:94
McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019; 381:1995-2008
Farxiga approved in the US for the treatment of heart failure in patients with heart failure with reduced ejection fraction [Internet].
[cited
2020
Jul
12].
Available
from:
h t t p s : / / w w w. a s t r a z e n e c a . c o m / m e d i a - c e n t re / p re s s releases/2020/farxiga-approved-in-the-us-for-the-treatment-ofheart-failure-in-patients-with-heart-failure-with-reduced-ejection-fr
action.html
Kramer CK, Ye C, Campbell S, Retnakaran R. Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A
Network Meta-Analysis. JACC Hear Fail [Internet]. 2018 Oct 1 [cited
2020
Jul
12];6(10):823–30.
Available
from:
https://pubmed.ncbi.nlm.nih.gov/30196071/
Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure. - Full Text View ClinicalTrials.gov [Internet]. [cited 2020 Jul 12]. Available from:
https://clinicaltrials.gov/ct2/show/NCT03619213?term=dapagliflozin&cond=heart+failure+with+preserved+ejection+fraction&rank=1
Vergara A, Jacobs-Cachá C, Soler MJ. Sodium-glucose cotransporter
inhibitors: Beyond glycaemic control. Clin Kidney J. 2019;12:322-325
Perico N, Ruggenenti P, Remuzzi G. ACE and SGLT2 inhibitors: the future for non-diabetic and diabetic proteinuric renal disease. Curr
Opin Pharmacol. 2017;33:34-40
Lundkvist P, Pereira MJ, Katsogiannos P, Sjöström CD, Johnsson E,
Eriksson JW. Dapagliflozin once daily plus exenatide once weekly in
obese adults without diabetes: Sustained reductions in body weight,
glycaemia and blood pressure over 1 year. Diabetes, Obes Metab.
2017; 19:1276-1288
Hollander P, Bays HE, Rosenstock J, Frustaci ME, Fung A, Vercruysse
F, et al. Coadministration of canagliflozin and phentermine for
weight management in overweight and obese individuals without
diabetes: A randomized clinical trial. In: Diabetes Care. 2017;40:632639
Scafoglio CR, Villegas B, Abdelhady G, Bailey ST, Liu J, Shirali AS, et
al. Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma. Sci Transl Med. 2018;10:
eaat5933 doi: 10.1126/scitranslmed.aat5933.

J Pak Med Assoc

